Ipca Laboratories Limited and Bhami’s Research Laboratory (BRL) have entered into a definitive global licensing agreement aimed at accelerating the development and commercialization of advanced biologic therapies for patients worldwide. The collaboration will provide Ipca access to BRL’s proprietary high-concentration subcutaneous biologics delivery platform for multiple monoclonal antibody products targeting oncology and inflammatory disease indications.
The partnership is expected to support the development of differentiated biologic therapies designed to improve patient convenience while expanding access to advanced treatment options across international markets. The technology platform focuses on enabling high-concentration formulations that can be administered subcutaneously, potentially simplifying treatment procedures and enhancing patient experience.
Pranay Godha, Managing Director and Chief Executive Officer of Ipca Laboratories, said the partnership combines Ipca’s scientific and manufacturing expertise with BRL’s formulation technology to advance affordable biologic therapies for patients battling cancer and autoimmune disorders globally.
Dr. Suryakanth M Pai, Co-Founder and Chief Executive Officer of BRL, noted that the collaboration represents an important opportunity to extend the reach of the company’s patented protein delivery technology. He added that the partnership is designed to support the development of innovative biologics that can improve convenience, accessibility, and safety for patients.
Akhil Shah, Director and Chief Executive Officer of WeTranslate, which supported the collaboration, stated that the alliance brings together a differentiated formulation platform and a globally established pharmaceutical organization capable of driving commercialization across multiple regions.
Founded in 1949, Ipca Laboratories has built a strong presence across global pharmaceutical markets, with exports contributing nearly half of its revenue. The company operates an integrated business model encompassing active pharmaceutical ingredients and finished dosage formulations, serving healthcare markets in more than 120 countries.
In recent years, Ipca has expanded its focus on biologics and biosimilars, particularly in oncology and inflammatory disease segments. The company has established a state-of-the-art biologics manufacturing facility in Pithampur, Madhya Pradesh, along with an advanced research and development center in Mumbai dedicated to biosimilar development.
